Next-IO™ Anti-iNOS Therapeutic Monoclonal Antibody Program {{ currentPage ? currentPage.title : "" }}

This program aims to develop anti-iNOS therapeutic monoclonal antibody for immuno-oncology.

Rationality when developing program:

  • (Nitric Oxide) NO is a small, impermanent gas molecule required by various physiological processes, including immune responses, neurotransmission, and vascular vasodilation.

  • The function of NO in cancer is complicated because it could promote but also inhibit the progression of tumors, depending on settings. High NO level may cause tumor cell apoptosis, and low levels will induce cell proliferation by stimulating angiogenesis.

  • Increased expression of (Inducible nitric oxide synthase) iNOS is significantly associated with angiogenesis, chemoresistance, metastasis and immune resistance in certain malignancies such as colorectal cancer, breast cancer, bladder cancer, gastric cancer, and melanoma.

  • Studies have reported iNOS expression is associated with poor prognosis in human cancers

In summary, iNOS may be a raising prognostic biomarker or therapeutic target to be studied.

Full article: Next-IO™ Anti-iNOS Therapeutic Monoclonal Antibody Program

{{{ content }}}